ResearcherNational Institutes of HealthActive in the last 2 years

Lin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9792-5410; OpenAlex author ID A5100351810. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Co-author DOI 10.1093/carcin/bgae056 ↗
Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on … Co-author DOI 10.1016/j.ajg.2022.06.005 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haorun Liu · 1 shared paper, 2022 · strength 0.20
- Paper Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human … DOI 10.1016/j.ajg.2022.06.005 ↗
Yujing Wang · 1 shared paper, 2022 · strength 0.20
- Paper Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human … DOI 10.1016/j.ajg.2022.06.005 ↗
Paloma Moreno · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
Nader N Hanna · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
Michael B. Ghadimi · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
Jochen Gaedcke · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
Yuuki Ohara · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
S. S. Yang · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
Azadeh Azizian · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗
S. Perwez Hussain · 1 shared paper, 2024 · strength 0.18
- Paper ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. DOI 10.1093/carcin/bgae056 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.